Drug store Rite Aid Corporation (NYSE:RAD) stated on Wednesday its net loss from continuing operations of USD17.3m (USD0.02 per share) for its third fiscal quarter ended 1 December 2018.
This marks a slight improvement when compared with net loss from continuing operations of USD18.2m (USD0.02 per share) in last year's third quarter.
Revenues from continuing operations of USD5.5bn was recorded for its third fiscal quarter ended 1 December 2018, a rise over revenues from continuing operations of USD5.4bn in the prior year's third quarter.
Adjusted EBITDA from continuing operations was USD142.8m or 2.6% of revenues for the third quarter, up USD0.7m versus the Adjusted EBITDA from continuing operations of USD142.1m or 2.7% of revenues for the same period last year, an increase of
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government